|Awarded On||February 21, 2019|
|Title||Neoadjuvant Treatment Response Monitoring of Breast Cancer With Molecular Photoacoustic Imaging|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Richard Bouchard|
*Pending contract negotiation
Close to 40,000 Americans will be diagnosed with triple-negative breast cancer (TNBC) in 2018, a subtype of invasive breast cancer with a poor prognosis. Patients with TNBC are preferably treated with neoadjuvant chemotherapy (NAC), which results in ~50% of patients having either pathologic compete response (pCR) or minimal residual disease upon resection. However, not all patients have a substantial response to NAC, and thus there is a dire clinical need for a non-invasive modality that is capable of monitoring therapy response to allow for timely modifications to one’s treatment plan or to assess the degree/location of residual disease. Recently, photoacoustic-ultrasonic (PA-US) imaging ha...